134
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development

, , , , , , , , , , , , & show all
Pages 363-370 | Received 05 Dec 2017, Accepted 22 Jun 2018, Published online: 24 Aug 2018

References

  • Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
  • Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.
  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
  • Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6.
  • Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87–101.
  • Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404–13.
  • Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000;133(3):165–75.
  • Islami F, Kamangar F. Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res (Phila). 2008;1(5):329–38.
  • Poynton AR, Walsh TN, O'Sullivan G, Hennessy TP. Carcinoma arising in familial Barrett's esophagus. Am J Gastroenterol. 1996;91(9):1855–6.
  • Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.
  • Anderson LA, Watson RG, Murphy SJ, Johnston BT, Comber H, Mc Guigan J, et al. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13(10):1585–94.
  • Oh DS, DeMeester SR, Dunst CM, Mori R, Lehman BJ, Kuramochi H, et al. Validation of a rodent model of Barrett's esophagus using quantitative gene expression profiling. Surg Endosc. 2009;23(6):1346–52.
  • Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, et al. Barrett's esophagus and animal models. Ann N Y Acad Sci. 2011;1232: 392–400.
  • Buskens CJ, Hulscher JB, van Gulik TM, Ten Kate FJ, van Lanschot JJ. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res. 2006;135(2):337–44.
  • Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis. 1999;20(9):1801–8.
  • Li Y, Martin RC, 2nd. Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus. 2007;20(5):372–8.
  • Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67(2):269–74.
  • Xu X, LoCicero J, 3rd, Macri E, Loda M, Ellis FH, Jr. Barrett's esophagus and associated adenocarcinoma in a mouse surgical model. J Surg Res. 2000;88(2):120–4.
  • Yamashita Y, Homma K, Kako N, Clark GW, Smyrk TC, Hinder RA, et al. Effect of duodenal components of the refluxate on development of esophageal neoplasia in rats. J Gastrointest Surg. 1998;2(4):350–5.
  • Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 2002;122(4):1101–12.
  • Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, et al. Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Ann Surg. 2013;258(1):82–8.
  • Schiffman SC, Li Y, Dryden G, Li X, Martin RC. Positive correlation of image analysis by mini-endoscopy with micro-PET scan and histology in rats after esophagoduodenal anastomosis. Surg Endosc. 2010;24(11):2835–41.
  • Budde MD, Gold E, Jordan EK, Frank JA. Differential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI. Clin Exp Metastasis. 2012;29(1):51–62.
  • Petre C, Ni Y, Marchal G, Yu J, Wevers M, Lauffer RB, et al. Detection and characterization of primary liver cancer in rats by MS-264-enhanced MRI. Magn Reson Med. 1996;35(4):532–9.
  • Yamaguchi M, Mitsuda M, Ezawa K, Nakagami R, Furuta T, Sekine N, et al. Artifact-reduced simultaneous MRI of multiple rats with liver cancer using PROPELLER. J Magn Reson Imaging. 2013;38(1):225–30.
  • Kosovec JE, Zaidi AH, Komatsu Y, Cothron K, Sato T, Thompson DV, et al. Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model. PLoS One. 2014;9(4):e93694.
  • Lu S, Lowe AW, Triadafilopoulos G, Hsiung PL, Hao Y, Crawford JM, et al. Endoscopic evaluation of esophago-gastro-jejunostomy in rat model of Barrett's esophagus. Dis Esophagus. 2009;22(4):323–30.
  • Greenawalt DM, Duong C, Smyth GK, Ciavarella ML, Thompson NJ, Tiang T, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer. 2007;120(9):1914–21.
  • Cheng P, Gong J, Wang T, Chen J, Liu GS, Zhang R. Gene expression in rats with Barrett's esophagus and esophageal adenocarcinoma induced by gastroduodenoesophageal reflux. World J Gastroenterol. 2005;11(33):5117–22.
  • Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW. Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology. 2006;131(3):925–33.
  • Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96(11):3071–83.
  • Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet. 2002;360(9345):1587–9.
  • Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, et al. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol. 2009;104(11):2673–80.
  • Kosovec JE, Zaidi AH, Kelly LA, Rotoloni CL, Vytlacil C, DiCarlo C, et al. Preclinical study of AUY922, a novel Hsp90 inhibitor, in the treatment of esophageal adenocarcinoma. Ann Surg. 2016;264(2):297–304.
  • Zaidi AH, Kosovec JE, Matsui D, Omstead AN, Raj M, Rao RR, et al. PI3K/mTOR Dual Inhibitor, LY3023414, Demonstrates Potent Antitumor Efficacy Against Esophageal Adenocarcinoma in a Rat Model. Ann Surg. 2017;226(1):91–98
  • Curvers WL, Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–1530; doi:10.1038/ajg.2010.171;
  • Malhotra U, Zaidi AH, Kosovec JE, Kasi PM, Komatsu Y, Rotoloni CL, et al. Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium. PLoS One. 2013;8(11):e78343.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.